Matthew T. NavarroExecutive Director, Advisory
Mr. Navarro is an Executive Director in Perella Weinberg Partners’ Advisory business. He focuses on advising clients in the Healthcare industry.
Mr. Navarro has more than 10 years of investment banking experience assisting companies on a wide range of strategic matters. During his tenure at Perella Weinberg Partners, he has advised a number of clients including Inotek Pharmaceuticals on its merger with Rocket Pharmaceuticals; Pernix Therapeutics on its strategic review which resulted in a restructuring of existing debt; Sprout Pharmaceuticals on its sale to Valeant Pharmaceuticals; Lumara Health on its sale to AMAG Pharmaceuticals; and Pamplona Capital on its acquisition of a majority stake in Alvogen.
Prior to joining Perella Weinberg Partners in October of 2013, Mr. Navarro was at Pfizer Inc., where he was responsible for assisting senior leadership in evaluating strategic alternatives for the Company’s various clinical pipeline candidates. Prior to that, Mr. Navarro was at Morgan Stanley in the firm’s Global Healthcare Investment Banking group. Mr. Navarro began his career as a financial programs / cost analyst at the Department of Homeland Security.
Mr. Navarro earned a Bachelor of Business Administration from The George Washington University and a Masters of Business Administration and Juris Doctor from the University of North Carolina.